Moleculin Biotech, Inc. Cash Flow Statement
MBRX|10 years of annual SEC 10-K data (FY2016-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 10 fiscal years. All figures from audited SEC 10-K filings.
Moleculin Biotech, Inc. used $24M in operating cash flow and negative free cash flow of $24M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -3.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$26.0M | -$29.8M | -$29.0M | -$15.9M | -$17.4M | -$13.2M | -$11.9M | -$9.8M | -$3.9M | -$748.4K |
| Depreciation & Amortization | $126.0K | $127.0K | $130.0K | $164.0K | $200.0K | $199.0K | $68.0K | $18.0K | $6.0K | $0 |
| Operating Cash Flow | -$23.9M | -$23.6M | -$27.6M | -$19.0M | -$17.8M | -$17.2M | -$12.2M | -$7.3M | -$3.8M | -$423.5K |
| Capital Expenditures | $13.0K | $124.0K | $67.0K | $19.0K | $376.0K | $52.0K | $417.0K | $28.0K | $21.0K | $0 |
| Free Cash Flow | -$23.9M | -$23.7M | -$27.7M | -$19.0M | -$18.1M | -$17.3M | -$12.6M | -$7.4M | -$3.8M | -$423.5K |